Navigation Links
Delcath Announces Agreement With European Institute of Oncology for Initial Launch of Hepatic Chemosat Delivery System in the European Union
Date:11/21/2011

a prestigious institution as the IEO, one of Europe's premier cancer treatment and research facilities. We expect to announce similar agreements with other major cancer centers in Europe in the near future, which will position us well to begin realizing the potential of the CHEMOSAT system in 2012."

About the IEOThe European Institute of Oncology was established in 1994 to implement an innovative model for health and advanced research in the international oncology field. The IEO's mission is focused on state-of-the-art cancer research and treatment, from basic laboratory research that grapples with the genetic roots of cancer, to advanced clinical research such as testing new drugs, all with the unifying goal of finding ways to treat patients more effectively.

About Delcath SystemsDelcath Systems, Inc. is a development stage specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi-arm Phase II trial to treat other liver cancers. The Company obtained authorization to affix a CE Mark for the Hepatic CHEMOSAT delivery system in April 2011. The Company has not yet received FDA approval for commercial sale of its system in the United States. For more information, please visit the Company's website at http://www.delcath.com/.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks a
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Delcath to Present at the Lazard Healthcare Conference on November 15
2. Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments
3. Delcath Systems to Report Third Quarter Progress and Conduct Conference Call
4. FDA Schedules Delcath Pre-New Drug Application Meeting Date
5. Delcath Announces Completion of Regulatory Notification Process in New Zealand
6. Delcath Announces Updated Efficacy Results From Phase 3 Trial of Chemosaturation for Melanoma Metastases in the Liver Presented at European Multidisciplinary Cancer Congress
7. Delcath to Present at the JMP Securities Healthcare Conference on September 28, 2011
8. Delcath Systems, Inc. Hosts Symposium on Chemosaturation at CIRSE Annual Meeting
9. Delcath Announces Top-Line Results From Metastatic Colorectal Cohort in Phase II Trial of Chemosaturation System
10. Delcath Announces Encouraging Top-Line Results From Hepatobiliary Cohort in Phase II Trial of Chemosaturation System
11. Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  Syneron Medical Ltd. (NASDAQ: ELOS ... that its new PicoWay® device has received CE Mark ... and pigmented lesions on any skin type. PicoWay is ... and 1064nm wavelengths, which utilizes Syneron,s proprietary PicoWay technology ... are trillionths of a second, known as picosecond pulses. ...
(Date:7/28/2014)... Concord Medical Services Holdings Limited ("Concord Medical" ... leading specialty hospital management solution provider and operator of ... in China , today announced that ... a special cash dividend of US$0.30 per ordinary share ... Company,s outstanding ordinary shares. The total expense for the ...
(Date:7/28/2014)...   Cardioxyl Pharmaceuticals, Inc. announced today the ... a novel potential treatment for acute decompensated heart failure ... has now initiated dosing of hospitalized patients with decompensated ... to further evaluate the drug,s safety and tolerability as ... I clinical trial evaluated the safety and tolerability of ...
Breaking Medicine Technology:Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4Concord Medical Declares Special Dividend 2Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 2
... plc (Nasdaq: JAZZ ) today announced that the ... Monday, February 27, 2011 at 4:30 p.m. EST/9:30 p.m. GMT. ... and review fourth quarter and full year 2011 financial results. ... accessed from the Investors section of the Jazz Pharmaceuticals, website ...
... PLEASANTON, Calif., Feb. 14, 2012  Thoratec Corporation (NASDAQ: ... circulatory support therapies to save, support and restore failing ... Leerink Swann 2012 Global Healthcare Conference on Thursday, February ... Investor Relations and Business Development, will provide an update ...
Cached Medicine Technology:
(Date:7/29/2014)... California (PRWEB) July 29, 2014 ... of the peer-reviewed journal Lipids in Health and ... value—of Nordic Naturals triglyceride-form best-selling Ultimate Omega®/ProOmega®. Consistently ... according to SPINS scan data, the product was ... to other omega-3 products in the marketplace. The ...
(Date:7/29/2014)... “Our years of experience with ... to insulate their homes properly simply due to ... heat transfer and conduction,” Clean Crawls says in ... released an article explaining exactly how heat ... bills. , To contact Clean Crawls for their ...
(Date:7/29/2014)... Bethesda, Maryland (PRWEB) July 29, 2014 ... has been named a 2014 ASAE Power of ... Flu-Focused," a public awareness campaign to encourage everyone age ... annually. , ASAE recognized NFID for its power ... drive awareness and action among consumers and professionals about ...
(Date:7/29/2014)... 2014 “Approximately 18% of our population ... common chronic illnesses,” Western Washington Medical Group says in ... for those suffering from allergies to seek medical attention. ... care each year in the United States,” they continue. ... of life for themselves, rather than seeking the appropriate ...
(Date:7/29/2014)... 29, 2014 The Eleventh Annual Business ... concluded with the $10,000 prize being presented to Ambika ... ) , The 11th Annual Summit was held on ... who can bring innovative products and services for the ... to have had such excellent array of young companies ...
Breaking Medicine News(10 mins):Health News:Study Shows Nordic Naturals® Triglyceride-Form Ultimate Omega®/ProOmega® More Effective Than Krill Oil, Salmon Oil, and Ethyl Ester Fish Oil 2Health News:Study Shows Nordic Naturals® Triglyceride-Form Ultimate Omega®/ProOmega® More Effective Than Krill Oil, Salmon Oil, and Ethyl Ester Fish Oil 3Health News:What’s The Point of Insulation? Clean Crawls Explains The Dangers of Heat Transfer in Recently Released Article 2Health News:National Foundation for Infectious Diseases Receives Top ASAE Honors for Keeping the Nation Flu-Focused 2Health News:Allergy Sufferers are Urged to Seek Medical Help in Recent Article by Western Washington Medical Group 2Health News:Allergy Sufferers are Urged to Seek Medical Help in Recent Article by Western Washington Medical Group 3Health News:Silicon Valley Boomer Venture Summit Names Bikanta Competition Winner 2
... majorities of older Americans experience significant and troubling gaps ... survey, "How Does It Feel? The Older Adult Health ... Foundation, a champion for improved geriatric care and longtime ... New York University,s College of Nursing. The poll ...
... Houston, TX - Accelerated partial breast irradiation (APBI) ... increasingly popular as a treatment choice for women ... rate of later mastectomy, increased radiation-related toxicities and ... (WBI), according to researchers from The University of ...
... Taking fish-oil supplements does not significantly lower the failure rate ... The study included about 200 North American kidney-failure patients with ... which provides access to the bloodstream for hemodialysis, a process ... The patients were randomly assigned to take fish-oil capsules or ...
... would get a better bang for its health-care buck in ... more in eliminating socio-environmental risk factors than in developing medicines. ... in Children: Elevating the Role of Environment, a new paper ... in the May issue of the Future of the ...
... testing older patients, blood vitamin D levels, there,s uncertainty ... not enough. The threshold amount has become controversial as ... resolve this debate, University of Washington researchers conducted an ... D must be circulating in the blood to lower ...
... parents of teenagers, friends can have as much effect ... according to prevention researchers. "Among friendship groups with ... parents are consistent and aware of your whereabouts, and ... their (children,s) whereabouts, then you are less likely to ...
Cached Medicine News:Health News:National poll: Low cost, lifesaving services missing from most older patients' health care 2Health News:National poll: Low cost, lifesaving services missing from most older patients' health care 3Health News:APBI associated with more mastectomies, toxicities, complications, compared to traditional radiation 2Health News:APBI associated with more mastectomies, toxicities, complications, compared to traditional radiation 3Health News:Fish Oil Doesn't Cut Failure Rate of Hemodialysis Grafts 2Health News:Environment key to preventing childhood disabilities 2Health News:Researchers determine vitamin D blood level for reducing major medical risks in older adults 2Health News:It takes a village to keep teens substance free 2
The Biopro Cox comb cup is manufactured from titanium and is porous coated on the outside of the shell. The Cox comb cup accommodates a polyethylene insert....
The Plasmacup SC satisfies two important requirements: high primary stability and a low friction bearing surface....
... The integration of Trabecular Metal ... proven implant design results in a ... not only meets surgeon demands for ... provides a wide variety of shell ...
The cementless BiHAPro cup combines proven concepts with the latest innovations in cementless THR....
Medicine Products: